BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34175784)

  • 1. Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers.
    Grodin EN; Burnette EM; Green R; Lim AC; Miotto K; Ray LA
    Drug Alcohol Depend; 2021 Aug; 225():108825. PubMed ID: 34175784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distress Tolerance and Craving for Cigarettes Among Heavy Drinking Smokers.
    Lim AC; Roche DJO; Ray LA
    J Stud Alcohol Drugs; 2018 Nov; 79(6):918-928. PubMed ID: 30573023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels.
    Nieto SJ; Enders CK; Witkiewitz K; O'Malley SS; Ray LA
    Alcohol Clin Exp Res; 2022 Dec; 46(12):2258-2266. PubMed ID: 36515648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline.
    Miranda R; O'Malley SS; Treloar Padovano H; Wu R; Falk DE; Ryan ML; Fertig JB; Chun TH; Muvvala SB; Litten RZ
    Alcohol Clin Exp Res; 2020 Jul; 44(7):1431-1443. PubMed ID: 32363592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals.
    Schacht JP; Anton RF; Randall PK; Li X; Henderson S; Myrick H
    Psychopharmacology (Berl); 2014 Sep; 231(18):3799-807. PubMed ID: 24647921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.
    Ray LA; Courtney KE; Ghahremani DG; Miotto K; Brody A; London ED
    Am J Drug Alcohol Abuse; 2015 Jan; 41(1):35-44. PubMed ID: 24949564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of varenicline on alcohol cue reactivity in heavy drinkers.
    Roberts W; Harrison ELR; McKee SA
    Psychopharmacology (Berl); 2017 Sep; 234(18):2737-2745. PubMed ID: 28600734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.
    Ray LA; Courtney KE; Ghahremani DG; Miotto K; Brody A; London ED
    Psychopharmacology (Berl); 2014 Oct; 231(19):3843-53. PubMed ID: 24733235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial.
    Ray LA; Green R; Enders C; Leventhal AM; Grodin EN; Li G; Lim A; Hartwell E; Venegas A; Meredith L; Nieto SJ; Shoptaw S; Ho D; Miotto K
    Am J Psychiatry; 2021 Sep; 178(9):818-828. PubMed ID: 34080890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study.
    Roberts W; Shi JM; Tetrault JM; McKee SA
    J Addict Med; 2018; 12(3):227-233. PubMed ID: 29438157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers.
    Roche DJ; Bujarski S; Hartwell E; Green R; Ray LA
    Pharmacol Biochem Behav; 2015 Jul; 134():92-8. PubMed ID: 25933795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
    Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
    Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
    Falk DE; O'Malley SS; Witkiewitz K; Anton RF; Litten RZ; Slater M; Kranzler HR; Mann KF; Hasin DS; Johnson B; Meulien D; Ryan M; Fertig J;
    JAMA Psychiatry; 2019 Apr; 76(4):374-381. PubMed ID: 30865232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder.
    Karl D; Bumb JM; Bach P; Dinter C; Koopmann A; Hermann D; Mann K; Kiefer F; Vollstädt-Klein S
    Psychopharmacology (Berl); 2021 Aug; 238(8):2179-2189. PubMed ID: 33846866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of topiramate on neural responses to alcohol cues in treatment-seeking individuals with alcohol use disorder: preliminary findings from a randomized, placebo-controlled trial.
    Wetherill RR; Spilka N; Jagannathan K; Morris P; Romer D; Pond T; Lynch KG; Franklin TR; Kranzler HR
    Neuropsychopharmacology; 2021 Jul; 46(8):1414-1420. PubMed ID: 33558678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals.
    Logge WB; Morris RW; Baillie AJ; Haber PS; Morley KC
    Psychopharmacology (Berl); 2021 May; 238(5):1291-1302. PubMed ID: 30788529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial.
    Miranda R; Ray L; Blanchard A; Reynolds EK; Monti PM; Chun T; Justus A; Swift RM; Tidey J; Gwaltney CJ; Ramirez J
    Addict Biol; 2014 Sep; 19(5):941-54. PubMed ID: 23489253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effects of Menstrual Cycle Hormones on Responses to Varenicline and Naltrexone Among Female Heavy Drinking Smokers.
    Green R; Roche DJO; Ray LA
    Alcohol Alcohol; 2022 Sep; 57(5):609-614. PubMed ID: 35470371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naltrexone and alcohol effects on craving for cigarettes in heavy drinking smokers.
    Green R; Bujarski S; Lim AC; Venegas A; Ray LA
    Exp Clin Psychopharmacol; 2019 Jun; 27(3):257-264. PubMed ID: 30628813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial.
    Grodin EN; Bujarski S; Towns B; Burnette E; Nieto S; Lim A; Lin J; Miotto K; Gillis A; Irwin MR; Evans C; Ray LA
    Transl Psychiatry; 2021 Jun; 11(1):355. PubMed ID: 34120149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.